Age-related macular degeneration may be associated with cognitive impairment
Older adults with low scores on tests of cognitive function,
including thinking, learning and memory appear more likely to have the early stages
of the eye disease age-related macular degeneration, according to a report in
the May issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
Age-related macular degeneration (AMD)-the leading cause
of visual impairment in industrialized nations-has long been thought to share
a common pathway with Alzheimer's disease, according to background information
in the article. First, both conditions involve similar changes in the brain and
eye, including the buildup of protein fragments known as beta-amyloid. "Second,
clinical studies suggest that AMD and Alzheimer's disease share similar vascular
risk factors, such as hypertension and cigarette smoking," the authors write.
"Both AMD and Alzheimer's disease have been linked to an increased risk of stroke."
Michelle L. Baker, M.D., of the University of Melbourne,
Victoria, Australia, and colleagues assessed 2,088 individuals age 69 to 97. Participants
underwent cognitive testing, retinal photography for the detection of AMD and
an extensive assessment of artery disease and its risk factors (including blood
pressure, smoking status and body mass index).
After controlling for age, sex, race and the center at
which they participated in the study, the one-fourth of individuals with the lowest
scores on one cognitive test were twice as likely to have early-stage AMD as were
individuals with higher scores. However, there was no association between AMD
and scores on a second cognitive test, dementia or Alzheimer's disease.
"In conclusion, we found an association between low cognitive
function and early AMD in this older population," the authors write. "These data,
along with others, provide further support that AMD and cognitive impairment may
share similar complex pathogenesis and risk factors."
The research reported in this article was supported by
contracts from the National Heart, Lung and Blood Institute, with additional contributions
from the National Institute of Neurological Disorders and Stroke. Additional support
was provided by a grant from the National Heart, Lung and Blood Institute and
by the National Heart Foundation.
|